Biopharmaceutical firms have initiated Phase III clinical trials evaluating messenger RNA (mRNA) therapies targeting rare liver and metabolic conditions. Lipid nanoparticle delivery innovations have significantly mitigated systemic toxicity concerns associated with earlier candidates.
Commercialization and Manufacturing
Scaling mRNA production requires specialized bioreactor capacity and cold-chain distribution channels. If approved, these therapies could establish a modular blueprint for addressing thousands of previously untreatable rare genetic diseases.